<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01781884</url>
  </required_header>
  <id_info>
    <org_study_id>2012-024</org_study_id>
    <nct_id>NCT01781884</nct_id>
  </id_info>
  <brief_title>Effects Of Gamma Aminobutyric Acid On The Progression Of New Onset Juvenile Type 1 Diabetes</brief_title>
  <official_title>Effects Of Gamma Aminobutyric Acid On The Progression Of New Onset Juvenile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, randomized, double-masked, placebo-controlled clinical study.&#xD;
      All groups will receive standard intensive diabetes treatment with insulin and life style&#xD;
      management. 60 subjects will be randomly assigned in a 1:1:1 ratio to receive placebo or&#xD;
      different dosage of GABA.&#xD;
&#xD;
      GABA is an amino acid produced from glutamate by glutamic acid decarboxylase. It was approved&#xD;
      for the treatment of hepatic coma, fibromyalgia, ataxia in China and is widely used as&#xD;
      supplement for the treatment of epilepsy, insomnia, stress and tobacco dependence. It has&#xD;
      been recently shown that GABA can prevent and reverse the development of diabetes in type 1&#xD;
      mice models. Participants will receive placebo or GABA for 52 weeks.&#xD;
&#xD;
      The study will consist of 4 weeks screening period, 2 weeks run-in period, 52 weeks treatment&#xD;
      period and 4 weeks follow-up period. Enrollment is expected to occur over 2 years.&#xD;
&#xD;
      To assess the efficacy and safety of GABA for the treatment of juvenile type 1 diabetes in&#xD;
      new onset subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Outcome:&#xD;
&#xD;
      The primary statistical hypothesis to be assessed in this study is whether the mean C-peptide&#xD;
      value for study subjects receiving GABA differs significantly from the mean value for placebo&#xD;
      subjects assessed at follow-up.&#xD;
&#xD;
      Secondary Outcome:&#xD;
&#xD;
      The study will examine the HbA1C and the daily dosage of insulin (units/kg).&#xD;
&#xD;
      Exploratory Endpoint:&#xD;
&#xD;
      The study will assess the effects of treatment on inflammatory markers and immunological&#xD;
      outcomes.&#xD;
&#xD;
      Major Inclusion Criteria:&#xD;
&#xD;
      Type 1 diabetes within past 6 months Age 5-21 years* At least one diabetes associated&#xD;
      autoantibody&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C-peptide value</measure>
    <time_frame>baseline and up to 52 weeks</time_frame>
    <description>The primary statistical hypothesis to be assessed in this study is whether the mean C-peptide value for study subjects receiving GABA differs significantly from the mean value for placebo subjects assessed at follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1C level</measure>
    <time_frame>baseline and up to 52 weeks</time_frame>
    <description>The study will examine the HbA1C level every 3 months from baseline and up to 52 weeks.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Daily dosage of insulin (units/kg).</measure>
    <time_frame>baseline and up to 52 weeks</time_frame>
    <description>The study will assess the daily dosage of insulin (units/kg).</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Gamma Aminobutyric Acid (GABA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GABA will be given 50mg/kg/Day, thrice daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gamma Aminobutyric Acid GABA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GABA will be given 100mg/kg/Day, thrice daily for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo will be given thrice daily for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gamma Aminobutyric Acid (GABA)</intervention_name>
    <description>two dosages will be used in this study. GABA: 50mg/kg/day and 100mg/kg/day</description>
    <arm_group_label>Gamma Aminobutyric Acid (GABA)</arm_group_label>
    <arm_group_label>Gamma Aminobutyric Acid GABA)</arm_group_label>
    <other_name>Gamma Aminobutyric Acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be between the ages of 5 and 21 years*&#xD;
&#xD;
          2. Be within 6-months of diagnosis of type 1 diabetes based on American Diabetes&#xD;
             Association (ADA) criteria&#xD;
&#xD;
          3. Must have stimulated C-peptide levels ≥0.2 pmol/ml measured during a mixed meal&#xD;
             tolerance test (MMTT) conducted at least 21 days from diagnosis of diabetes and within&#xD;
             one month of randomization&#xD;
&#xD;
          4. Presence of at least one diabetes-related autoantibody&#xD;
&#xD;
          5. Must be willing to comply with intensive diabetes management and monitor glucose with&#xD;
             glucometer.&#xD;
&#xD;
          6. If participant is female with reproductive potential, she must be willing to avoid&#xD;
             pregnancy during the whole study period and have a negative pregnancy test&#xD;
&#xD;
          7. Parents and participants must sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Be currently pregnant or lactating or anticipate getting pregnant during the study&#xD;
             period.&#xD;
&#xD;
          2. Type 2 diabetes and other specific types of diabetes.&#xD;
&#xD;
          3. Require use of systemic immunosuppressant, steroids or other medications that can&#xD;
             affect glucose metabolism.&#xD;
&#xD;
          4. Have a history of malignancies&#xD;
&#xD;
          5. Be currently using non-insulin pharmaceuticals to affect glycemic control&#xD;
&#xD;
          6. Have any acute or chronic complicating medical issues or abnormal clinical laboratory&#xD;
             results that interfere with study conduct or cause increased risk.&#xD;
&#xD;
          7. Have a history of epilepsy, significant head trauma or cerebrovascular accident or&#xD;
             clinical features of continuous motor unit activity in proximal muscles&#xD;
&#xD;
          8. Inability or unwillingness to comply with the provisions of this protocol&#xD;
&#xD;
          9. Have an active infection or positive PPD test result.&#xD;
&#xD;
         10. Have serologic evidence of current or past HIV, Hep B, or Hep C infection.&#xD;
&#xD;
         11. Be with acute complications of diabetes (diabetic ketoacidosis, nonketotic hypersmolar&#xD;
             coma, diabetic lactic acidosis)&#xD;
&#xD;
         12. Have a history of chronic renal failure, serum creatinine higher than 177umol/L&#xD;
&#xD;
         13. Have a history of impaired liver function, ALT or AST level elevated more than (or&#xD;
             equal to) 2.5 times of upper limmit normal.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yiming Li, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qinghua Wang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Michale's Hospital, University of Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Endocrinology and Metabolism，Huashan hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhaoyun Zhang</last_name>
      <phone>86-21-52888286</phone>
    </contact>
    <contact_backup>
      <last_name>Yi Wang</last_name>
      <phone>86-21-52887022</phone>
    </contact_backup>
    <investigator>
      <last_name>Yiming Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qinghua Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>January 12, 2013</study_first_submitted>
  <study_first_submitted_qc>January 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2013</study_first_posted>
  <last_update_submitted>January 31, 2013</last_update_submitted>
  <last_update_submitted_qc>January 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Zhaoyun Zhang</investigator_full_name>
    <investigator_title>clinical professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>gamma-Aminobutyric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

